Skip to content
Marksans Pharma logo

Marksans Pharma

MARKSANS NSE
₹301.65 −13.65 (−4.33%)
P/E
26.44
View as Markdown
MCP
Close 4 Nov 2026 ₹301.65 +117.07 +63.4% 1Y
Start ₹184.58

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
18.80%
Debt to Equity
0.11
EPS (TTM)
₹11.41
Book Value
₹66.71
Market Cap
—
P/E (TTM)
26.44
P/B
4.52
ROE
15.20%
Dividend Yield
0.29%
EBITDA
₹683 Cr
52W High
₹350.95
52W Low
₹155.00
Day Range
₹296.60 – ₹327.00
Volume
59,61,751

Peer Comparison

Healthcare › Pharmaceuticals

Marksans Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Marksans Pharma (this company)
₹301.6526.44₹14,562 Cr4.520.29%15.20%18.80%₹3,172 Cr₹521 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.650.44%16.25%18.30%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

64 Good

Data confidence 100/100

Category scores

Quality
55
Good
Returns, margins, earnings quality 22% weight
Valuation
70
Strong
Cheap vs sector & own history 24% weight
Growth
59
Good
Sales & profit trajectory 9% weight
Financial Health
76
Strong
Solvency, leverage, coverage 9% weight
Momentum
75
Strong
Trend strength, vol-adjusted 12% weight
Ownership
55
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish775
OscillatorsNeutral171
Moving AveragesStrong Bearish604

Key readings

RSI (14)
44.90
Neutral
MACD (12,26,9)
−3.36
Bullish
SMA (50)
320.21
Bearish
SMA (200)
241.88
Bullish

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+12.70%
5Y+16.49%
3Y+16.80%
1Y+12.50%
TTM+19.57%

Net profit

Net profit growth by window
10Y+17.60%
5Y+11.94%
3Y+16.59%
1Y+9.66%
TTM+48.01%

Operating cash flow

Operating cash flow growth by window
10Y+30.90%
5Y+20.67%
3Y+24.56%
1Y+121.26%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+5.14 pp
5Y−4.34 pp
3Y+2.01 pp
1Y+0.05 pp
TTM+3.15 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹767 Cr
Mar 2018₹913 Cr
Mar 2019₹1,000 Cr
Mar 2020₹1,134 Cr
Mar 2021₹1,376 Cr
Mar 2022₹1,491 Cr
Mar 2023₹1,852 Cr
Mar 2024₹2,177 Cr
Mar 2025₹2,623 Cr
Mar 2026₹2,951 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹11.00 Cr
Mar 2018₹36.00 Cr
Mar 2019₹80.00 Cr
Mar 2020₹121 Cr
Mar 2021₹239 Cr
Mar 2022₹187 Cr
Mar 2023₹265 Cr
Mar 2024₹315 Cr
Mar 2025₹383 Cr
Mar 2026₹420 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹210 Cr −11.9% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk medium

Marksans Pharma trades at ₹301.65 as of 2026-11-04 with a market cap of ₹14,561.89 crore, a trailing P/E of 26.44, and a debt-to-equity ratio of 0.11. The stock has delivered a 1-year CAGR of 74% and compounded sales growth of 17% over 3 years, while ROE stands at 13.76% and ROCE at 17.54%.

Bull Case 8
  • TTM profit growth of 48% signals a sharp acceleration in earnings, well above the 5-year compounded profit growth of 12%
  • Near-zero leverage with a debt-to-equity ratio of just 0.11, providing significant financial flexibility and balance sheet resilience
  • Consistent double-digit sales compounding at 13% over 10 years, 16% over 5 years, and 17% over 3 years demonstrates durable revenue momentum
  • ROCE of 17.54% indicates efficient capital deployment and healthy return generation on invested capital
  • 10-year compounded profit growth of 18% reflects a long track record of sustained earnings expansion
  • TTM revenue growth of 20% outpaces the 10-year sales CAGR of 13%, suggesting the business is in an acceleration phase
  • Stock has delivered a 5-year CAGR of 35% and a 10-year CAGR of 20%, reflecting sustained long-term wealth creation
  • ROE has averaged 17% over 5 and 10-year periods, indicating consistent shareholder return generation
Bear Case 7
  • Price-to-book ratio of 4.52 suggests the stock is priced at a significant premium to its book value
  • Dividend yield of just 0.29% offers negligible income return, indicating most returns depend entirely on capital appreciation
  • The stock trades 14% below its 52-week high of ₹350.95, suggesting recent selling pressure or profit booking after a sharp rally
  • Last year ROE of 15% and current ROE of 13.76% are both below the 10-year average ROE of 17%, indicating a declining trend in return efficiency
  • The 1-year stock CAGR of 74% far exceeds the TTM profit growth of 48%, implying that a portion of the re-rating is sentiment-driven rather than fundamentals-driven
  • The stock has nearly doubled from its 52-week low of ₹155, raising the risk of mean reversion if broader market conditions weaken
  • 5-year compounded profit growth of 12% lags the 5-year sales CAGR of 16%, suggesting periods of margin compression within the medium-term track record

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

34d ago

TL;DR: The only recent news for Marksans Pharma is a routine investor-relations disclosure about a group meet with institutional investors, which should have no direct effect on fundamentals or the share price. No new positive or negative business developments came up in this news set, so it gives no signal on whether the trend is improving or getting worse. Taking part in investor conferences suggests management is keeping in touch with institutions. Investors should look to upcoming quarterly results, US and UK formulation demand, and margin trends for clearer direction.

Neutral 1
  • Ashwamedh-Elara investor meet attendance Sep 1

    Marksans Pharma will attend the Ashwamedh - Elara India Dialogue 2026, a group meet on September 2, 2026, held in person at Hyatt, Santacruz East, Mumbai. The company said it will not share any unpublished price-sensitive information.

Quarterly Results

₹ Cr
MARKSANS quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
500
531
586
560
591
642
682
708
620
720
754
856
841
Expenses
398
417
453
450
462
495
543
582
520
576
594
661
628
Operating Profit
102
114
133
110
128
147
139
127
100
144
161
195
213
OPM %
20%
21%
23%
20%
22%
23%
20%
18%
16%
20%
21%
23%
25%
Other Income
10
19
5
17
15
0
28
15
6
22
20
35
25
Interest
2
2
3
5
3
3
3
3
6
6
6
6
7
Depreciation
14
18
22
21
20
20
21
23
23
27
24
24
25
PBT
97
114
113
100
120
125
143
116
77
133
151
200
207
Tax %
27%
26%
26%
23%
26%
22%
27%
22%
24%
26%
25%
25%
23%
Net Profit
70
84
83
78
89
98
105
91
58
99
114
149
159
EPS (₹)
1.52
1.84
1.84
1.73
1.96
2.13
2.31
2
1.29
2.17
2.5
3.27
3.47

Profit & Loss

₹ Cr
MARKSANS profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
797
893
767
913
1,000
1,134
1,376
1,491
1,852
2,177
2,623
2,951
3,172
Expenses
612
757
722
834
868
942
1,037
1,232
1,513
1,719
2,090
2,350
2,458
Operating Profit
185
136
45
78
132
192
340
259
340
459
533
601
714
OPM %
23%
15%
6%
9%
13%
17%
25%
17%
18%
21%
20%
20%
22%
Other Income
3
9
7
8
5
0
7
42
59
50
66
82
102
Interest
16
10
7
10
10
9
8
8
9
11
12
24
25
Depreciation
16
28
30
27
23
27
36
45
52
74
83
99
100
PBT
156
107
15
50
104
157
302
248
338
424
504
561
691
Tax %
28%
23%
24%
28%
23%
23%
21%
25%
21%
26%
24%
25%
—
Net Profit
112
83
11
36
80
121
239
187
265
315
383
420
521
EPS (₹)
2.67
1.92
0.22
0.8
1.87
2.95
5.76
4.51
5.88
6.92
8.4
9.22
11.41
Div. Payout %
4%
21%
23%
6%
3%
3%
4%
6%
9%
9%
10%
10%
—

Balance Sheet

₹ Cr
MARKSANS balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
41
41
41
41
41
41
41
41
45
45
45
45
Reserves
326
401
392
430
502
595
846
1,161
1,700
2,020
2,422
2,978
Borrowings
101
100
110
118
100
30
34
111
123
244
322
343
Other Liabilities
207
180
209
142
160
236
307
323
322
372
451
489
Total Liabilities
676
722
752
731
802
902
1,228
1,636
2,190
2,681
3,240
3,856
Fixed Assets
166
270
267
279
270
303
309
428
486
776
982
1,044
CWIP
0
0
0
0
0
0
12
3
10
9
27
59
Investments
0
0
0
0
0
0
0
0
1
27
1
0
Other Assets
510
452
484
451
533
599
907
1,205
1,694
1,869
2,230
2,753
Total Assets
676
722
752
731
802
902
1,228
1,636
2,190
2,681
3,240
3,856

Cash Flow

₹ Cr
MARKSANS cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
155
31
14
50
27
233
179
99
237
230
207
458
Investing
−33
−123
−21
−39
−13
−60
−45
−84
−259
−141
−49
−249
Financing
17
−58
−3
3
−21
−114
−15
80
198
−69
−65
−71
Net Cash Flow
138
−150
−10
15
−7
60
118
94
176
21
93
138
Free Cash Flow
118
−101
−14
11
14
174
133
53
184
22
35
329
CFO/OP
108
43
31
73
41
134
67
66
88
77
62
99

Ratios

MARKSANS financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
84
89
118
71
64
78
72
97
82
76
75
80
Inventory Days
107
120
151
152
215
155
248
216
192
217
270
278
Days Payable
88
85
129
54
78
71
103
102
91
94
98
96
Cash Conversion Cycle
103
124
140
169
202
163
217
211
183
199
247
261
Working Capital Days
17
59
77
70
97
87
104
121
122
129
142
149
ROCE %
44%
23%
4%
10%
18%
25%
38%
23%
22%
21%
20%
19%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Marksans Pharma insights

72 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 43.87%
  • Public 27.05%
  • FIIs 19.06%
  • DIIs 5.54%
  • Others 4.48%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Marksans Pharma

What does Marksans Pharma Ltd do?
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products
Where is Marksans Pharma Ltd (MARKSANS) listed?
Marksans Pharma Ltd trades as MARKSANS on the NSE and under code 524404 on the BSE.
Which sector does Marksans Pharma Ltd belong to?
Marksans Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Marksans Pharma Ltd?
Marksans Pharma Ltd trades at a PE ratio of 26.44 as of 4 Nov 2026, on earnings per share of ₹11.41, against a book value of ₹66.71 per share.
What is the 52-week high and low of Marksans Pharma Ltd?
Over the last 52 weeks Marksans Pharma Ltd has traded between ₹155 and ₹350.95 as of 4 Nov 2026.
Does Marksans Pharma Ltd pay dividends?
Marksans Pharma Ltd has a dividend yield of 0.29%.
What is the Return on Equity (ROE) of Marksans Pharma Ltd?
Marksans Pharma Ltd reported a return on equity of 15.20%. Its debt-to-equity ratio is 0.11.

Company Information

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products

Website marksanspharma.com
CEO Mr. Mark B. Saldanha
Employees 1,840
Listed 21 Jan 2002
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MARKSANS.md for Marksans Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month